Advertisement

Stenosis and Vascular Damage as an Experimental Model of Arterial Thrombosis: A Role for Prostanoids

  • Marco Prosdocimi
Part of the NATO ASI Series book series (NSSA, volume 177)

Abstract

Arachidonic acid, a membrane bound fatty acid, is released following a variety of stimuli. Upon release the fatty acid undergoes a series of reactions which may yield prostanoids. Prostanoids are potent agents capable of eliciting profound effects within their immediate environment. One such effect, the formation of an arterial thrombus, is regulated by the interaction of the endothelium and subendothelium of the blood vessel wall with platelets and white blood cells (de Gaetano et al., 1986; Dejana, 1987; Prosdocimi et al., 1988a). Once activated, platelets may aggregate to generate the thrombus, often formed in patients with coronary atherosclerosis. This process may, in turn, lead to an active phase of unstable angina or to a myocardial infarction (see for review Fuster et al., 1988). In addition, it has been suggested that the thrombotic procest plays a major role in provoking cerebral and peripheral ischemic pathology (Folts, 1980; Born et al., 1983; Kistler et al., 1984; Fitzgerald et al. 1984; Hess et al., 1985). Thus, the study of prostanoids in arterial thrombosis is an area of intensive investigation. This article will focus on the role of two arachidonate metabolites, prostacyclin and thromboxane, and the application of an experimental model of arterial thrombosis induced by vessel wall damage and flow alterations.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aiken, J.W., Shebuski, R.J., Miller, 0.V., and Gorman, R.R., 1981, Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis, J. Pharmacol. Exp. Ther., 219: 299.PubMedGoogle Scholar
  2. Ashton, J.H., Schmitz, J.M., Campbell, W.B., Ogletree, M.L., Raheja, S., Taylor, A.L., Fitzgerald, C., Buja, L.M. and Willerson, J.T., 1986, Inhibition of cyclic flow variations in stenosed canine coronary arteries by thromboxane A2/prostaglandin H2 receptor antagonists, Circulations Res, 59: 568.CrossRefGoogle Scholar
  3. Bertha, B.G., and Folts, J.D., 1984, Inhibition of epinephrine-exacerbated coronary thrombus formation by prostacyclin in the dog, J. Lab. Clin. Med., 103:204.Google Scholar
  4. Bolli, R., Brandon, T.A., Mace, M.L., and Weilbaecher, D.G., 1985, Influence of alpha-adrenergic blockade on platelet mediated thrombosis in stenosed canine coronary arteries, Cardiovasc. Res., 19: 146.CrossRefGoogle Scholar
  5. Born, G.V.R., Görög, P., and Begent, N.A., 1983, The biologic background to some therapeutic uses of aspirin, Am. J. Med., 14: 2.CrossRefGoogle Scholar
  6. Bush, L.R., Campbell, W.B., Kern, K., Tilton, G.D., Apprill, P., Ashton, J., Schmitz, J., Buja, L.M., and Willerson, J.T., 1984a, The effects of alpha2-adrenergic and serotoninergic antagonists on cyclic blood flow alterations in stenosed canine coronary arteries, Circ. Res., 55: 642.CrossRefGoogle Scholar
  7. Bush, L.R., Campbell, W.B., Buja, L.M., Tilton, G.D., and Willerson, J. T., 1984b, Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries, Circulation, 69: 1161.CrossRefGoogle Scholar
  8. Bush, L.R., 1987, Effects of the serotonin antagonists, cyproheptadine, ketanserin and mianserin, on cyclic flow reductions in stenosed canine coronary arteries, J. Pharmacol. Exp. Ther., 240: 674.PubMedGoogle Scholar
  9. Cerletti, C., Gambino, M.C., Garattini, S., and de Gaetano, G., 1986a, Biochemical selectivity of oral versus intravenous aspirin in rats. Inhibition by oral aspirin of cyclooxygenase activity in platelets and presystemic but not systemic vessels, J. Clin. Invest., 78: 323.CrossRefGoogle Scholar
  10. Cerletti, C., Minoldo, S., Bucchi, F., Del Maschio, A., and de Gaetano, G., 1986b, Requirement of ADP for arachidonic acid-induced platelet aggregation: studies with selective thromboxane-synthase inhibitors, Biochem. Pharmacol., 35: 1201.CrossRefGoogle Scholar
  11. Coller, B.S., Folts, J.D., Scudder L.E., and Smith, S.R., 1986, Anti-thrombotic effect of a monoclonal antibody to the platelet glycoprotein Iib/IIIa receptor in an experimental animal model, Blood, 68: 783.PubMedGoogle Scholar
  12. De Gaetano, G., Cerletti, C., Dejana, E., and Vermylen, J., 1986, Current issues in thrombosis prevention with antiplatelet drugs, Drugs, 31: 517.CrossRefGoogle Scholar
  13. Dejana, E., de Castellarnau, C., Balconi, G., Rotilio, D., Pietra, A., and de Gaetano, G., 1982, AD6, a coronary dilating agent, stimulates PGI2 production in rat aorta ex vivo and in human endothelial cells in culture, Pharmacol. Res. Commun., 14: 719.CrossRefGoogle Scholar
  14. Dejana, E., 1987, Endothelium, vessel injury and thrombosis, Haematologica, 72: 89.PubMedGoogle Scholar
  15. Fitzgerald, D.J., Smith, B., Pedersen, A.K., and Brash, A.L., 1984, Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation, N. Engl. J. Med., 310: 1065.CrossRefGoogle Scholar
  16. Fitzgerald, D.J., Wright, F., and Fitzgerald, G.A., 1987, Platelet-dependent reocclusion following coronary thrombolysis with tissue plasminogen activator. Clin. Res., 35: 278A (Abstr.).Google Scholar
  17. Folts, J.D., Crowell, E.D., and Rowe, G.G., 1976, Platelet aggregation in partially obstructed vessels and its elimination with aspirin, Circulation, 54: 365.CrossRefGoogle Scholar
  18. Folts, J.D., 1980, Platelet aggregation in stenosed coronary or cerebral arteries: A mechanism for sudden death?, Wisc. Med. J., 79:24. Folts, J.D., Gallagher, K., and Rowe, G.G., 1982, Blood flow reductions in stenosed canine coronary arteries: vasospasm or platelet aggregation? Circulation, 65: 248.CrossRefGoogle Scholar
  19. Foltz, J.D., and Rowe, G.G., 1988, Epinephrine potentiation of in vivo stimuli reverses aspirin inhibition of platelet thrombus formation in stenosed canine coronary arteries, Thromb. Res., 50: 507.CrossRefGoogle Scholar
  20. Fuster, V., Badimon, L., Cohen, M., Ambrose, A., Badimon, J.J., and Chesebro, J., Insights into the pathogenesis of acute ischemic syndromes, Circulation, 77: 1213.CrossRefGoogle Scholar
  21. Galli, C., Agradi, E., Petroni, A., and Socini, A., 1980,effects of 8-monochloro-3-beta-diethylaminoethyl-4-methyl-7-ethoxy carbonyl methoxy coumarin (AD6) on aggregation, arachidonic acid metabolism and thomboxane B2 formation in human platelets, Pharmacol. Res. Commun., 12: 329.Google Scholar
  22. Hess, H., Mietaschk, A., and Deichsel, G., 1985, Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease, Lancet, 1: 415.CrossRefGoogle Scholar
  23. Kistler, J.P., Ropper, A.H., and Heros, R.C., 1984, Therapy of ischemic cerebral vascular disease due to atherothrombosis, N. Engl. J. Med., 31: 27.CrossRefGoogle Scholar
  24. Kowey, P.R., Verrier, R.L., Lown, B., and Handin, R.I., 1983, Influence of intracoronary platelet aggregation on ventricular electrical properties during partial coronary artery stenosis, Am. J. Cardiol., 51: 596.CrossRefGoogle Scholar
  25. Machleidt, C., Rose P., Mittmann, U., and Thomae K., 1985, Prevention of coronary platelet aggregation with a phosphodiesterase inhibitor RX-RA 69, Throm. Res., 37: 595.CrossRefGoogle Scholar
  26. Marcus, A.J., Weksler, B.B., Jaffe, E.A., and Broekman, M.J., 1980, Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells, J. Clin. Invest., 66: 979.CrossRefGoogle Scholar
  27. Nichols, T.C., Bellinger, D.A., Johnson, T.A., Lamb, M.A., and Griggs, T.R., 1986, Von Willebrand’s disease prevents occlusive thrombosis in stenosed and injured porcine coronary arteries, Circ. Res., 59: 15.CrossRefGoogle Scholar
  28. Papp, A.C., Crowe, L., Pettigrew, L.C., and Wu, R.K., 1986, Production of eicosanoids by deendothelialized rabbit aorta: interaction between platelets and vascular wall in the synthesis of prostacyclin, Thromb. Res., 42: 549.CrossRefGoogle Scholar
  29. Petroni, A., Socini, A., Blasevich, M., Borghi, A., Galli C., Differential effects of various vasoactive drugs on basal and stimulated levels of TXB2 and 6-ketoPGFlalpha in rat brain, Prostaglandins, 29: 579.Google Scholar
  30. Prosdocimi, M., Finesso, M., Gorio, A., Languino, L.R., Del Maschio, A., Castagnoli, M.N., de Gaetano, G., and Dejana, E., 1985a, Coronary and systemic 6-ketoprostaglandin Flalpha and thromboxane B2 during myocardial ischemia in dog, Am. J. Physiol., 248:H-493.Google Scholar
  31. Prosdocimi, M., Finesso, M., Tessari, F., Gorio, A., Languino, L.R., de Gaetano, G., and Dejana, E., 1985b, Inhibition by AD6 (8-monochloro-3-beta-diethylaminoethyl-4-methyl-7- ethoxycarbonylmethoxy coumarin) of platelet aggregation in dog stenosed coronary artery, Thromb. Res., 39: 399.CrossRefGoogle Scholar
  32. Prosdocimi, M., Zatta, A., Gorio, A., Zanetti, A., and Dejana, E., 1986, Action of AD6 (8-monochloro-3-beta-diethylaminoethyl-4-methyl-7-ethoxycarbonylmethoxy coumarin) on human platelets in vitro, Naunyn-Schmiedeberg’s Arch. Pharmacol., 332: 305.CrossRefGoogle Scholar
  33. Prosdocimi, M., Finesso, M., and Dejana, E., 1988a, A critical approach to the study of new agents for the prevention of arterial thrombosis: a comment, Pharmacol. Res. Commun., 20: 1.CrossRefGoogle Scholar
  34. Prosdocimi, M., Finesso, M., Banzatto, N., Zanetti, A., de Gaetano, G., and Dejana, E., 1988b, Prostacyclin release in the coronary circulation during sustained stimulation in in vitro and in vivo experimental systems, Thromb. Haemost., 59: 180.CrossRefGoogle Scholar
  35. Prosdocimi, M., Zatta, A., and Finesso, M., Stenosis and vascular damage as a cause of thrombosis in the dog femoral artery, Naunyn-Schmiedeberg’s Arch. Pharmacol., in press.Google Scholar
  36. Simpson, J.P., Smith, B.C., Rosenthal, G., and Lucchesi, R.B., 1986, Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury, J. Pharmacol. Exp. Ther., 238: 497.PubMedGoogle Scholar
  37. Tada, M., Esumi, K., Yamagishi, M., Kuzuya, T., Matsuda, H., Abe, H., Uchida, Y., and Murao, S., 1984, Reduction of prostacyclin synthesis as a possible cause of transient flow reduction in a partially constricted canine coronary artery, J. Mol. Cell Cardiol., 16: 1137.CrossRefGoogle Scholar
  38. Uchida, Y., Yoshimoto, N., and Murao, S., 1980, Angiographic changes in the coronary artery associated with cyclical reductions of coronary blood pressure, JPN Circ. J., 44: 163.CrossRefGoogle Scholar
  39. Uchida, Y., and Murao, S., 1981, Effects of thromboxane synthetase inhibitors on cyclical reduction of coronary blood flow in dogs, JPN Heart J, 22: 971.Google Scholar
  40. Weselcouch, O.E., Humphrey, W.R., and Aiken, J.W., 1987, Effects of low doses of aspirin and dipyridamole on platelet aggregation in the dog coronary artery, J. Pharmacol. Exp. Ther., 240: 37.PubMedGoogle Scholar
  41. Zanetti, A., Zatta, A., Prosdocimi, M., and Dejana, E., The effect of AD6 (8-monochloro-3-beta-diethylamino-ethyl-4-methyl-7-ethoxycarbonylmethoxy coumarin) on washed human platelet aggregation induced by platelet activating factor (PAF) and epinephrine, Europ. J. Pharmacol., 128: 119.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • Marco Prosdocimi
    • 1
  1. 1.Fidia Research LaboratoriesAbano TermeItaly

Personalised recommendations